Share on

Middle East and Africa Schizophrenia Drugs Market Research Report – Segmented By Therapeutic Class, Treatment & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends & Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 8021
Pages: 145
Formats: report pdf report excel report power bi report ppt

Middle East and Africa Schizophrenia Drugs Market (2023 to 2028)

The size of the Middle East and Africa Schizophrenia Drugs Market was worth USD 0.58 billion in 2023 and estimated to be growing at a CAGR of 2.56%, to reach USD 0.66 billion by 2028. 

The Middle East and Africa region accounted for the lowest share in the global market in 2020 due to weak infrastructure in both regions. However, although the market is still in its nascent stages, it is expected to experience healthy growth during the forecast period. Based on the study carried out and the result formulated by the Psychiatric Association, it was recognized that 1 in 24 mental health patients suffered from serious mental disorders that include disorders like severe psychotics. The sharp increase in the number of people with serious mental disorders increases the burden on the health system, health services, and health service providers. The World Health Organization (WHO) recently estimated that one in four people, or about 25% of the world's population, suffers from mental illness in both the developed and developing world.

The regional governments emphasize creating a satisfactory and reliable level of awareness of mental diseases and associated symptoms. Between 30-40% of mental illnesses in the UAE are linked to schizophrenia, while between 30-40% have bipolar disorder. In the Kingdom of Saudi Arabia, mental disorders are seen as below figures: major depressive disorder (41.78%), followed by anxiety disorders (22.78%), substance-induced psychotic disorder (11.48%), schizophrenia (8.92%), and mental retardation (7.32%). According to physicians, the frequency of diagnosis of schizophrenia in Africa varies from 6 to 61%. The African population has experienced social and cultural alterations which developed into mental pathology.

As a result, leading market players are investing in developing highly effective and safe drugs for treating patients with psychotic illnesses with fewer side effects. In addition, main players are bringing innovative new products to the market, such as injectable drugs, which can reduce the frequency of medication and pill anxiety of taking drugs. All these aforementioned factors boost the market during the forecast period.

However, the increase in drug addiction cases associated with these drugs and the expiration of patents on major drugs are hampering the overall market growth. Additionally, the social stigma associated with a mental disorder may challenge the market.

This research report on the MEA schizophrenia drugs market has been segmented and sub-segmented into the following categories.

By Therapeutic Class:

  • Second generation anti-psychotics
    • Risperdal
    • Invega
    • Zyprexa
    • Geodon
    • Seroquel
    • Latuda
    • Aristada
    • Fanapt
    • Saphris
    • Vraylar
  • Third generation anti-psychotics  
  • Others    

By Treatment:

  • Oral anti-psychotics       
  • Injectable anti-psychotics 

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

The Middle Eastern region held the largest market share in the MEA schizophrenia drugs market in 2020 and is expected to continue with this trend during the forecast period. In addition, the growing awareness of mental healthcare awareness in Middle Eastern countries like Saudi Arabia, Qatar, United Arab Emirates, and Bahrain will drive the market demand during the forecast period.

The Saudi Arabia market share will grow attributed to various factors like an increase in depression, stress, and mental illnesses due to increased working hours, disposable income per capita, and the presence of a well-established and technologically advanced health system. On the other hand, as the fastest-growing region, the third-largest market share of the MEA market is held by the UAE. The growth in this region is accounted with a high incidence of chronic and mental illnesses mainly due to the hectic lifestyles, advancing health care, growing awareness, and government involvement in increasing health spending.

KEY MARKET PLAYERS:

Some of the major companies dominating the market by their products and services include Johnson & Johnson, Sumitomo Dainippon, Eli Lilly, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Alkermes, Vanda Pharma, Allergan, and Pfizer.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample